Treatment of Early Allergic and Late Inflammatory Symptoms of Allergic Rhinitis with <i>Petasites Hybridus</i> Leaf Extract (Ze 339): Results of a Noninterventional Observational Study in Switzerland

The primary objective of this noninterventional, observational study was to assess the effectiveness of the <i>Petasites hybridus</i> leaf extract (Ze 339) on early allergic and late inflammatory symptoms of allergic rhinitis in Swiss outpatients. This study was conducted by general prac...

Full description

Saved in:
Bibliographic Details
Main Authors: Maren Blosa (Author), Julia Uricher (Author), Sabine Nebel (Author), Catherine Zahner (Author), Veronika Butterweck (Author), Jürgen Drewe (Author)
Format: Book
Published: MDPI AG, 2021-02-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_e7ef3da18d5f41c0a534831c59519afc
042 |a dc 
100 1 0 |a Maren Blosa  |e author 
700 1 0 |a Julia Uricher  |e author 
700 1 0 |a Sabine Nebel  |e author 
700 1 0 |a Catherine Zahner  |e author 
700 1 0 |a Veronika Butterweck  |e author 
700 1 0 |a Jürgen Drewe  |e author 
245 0 0 |a Treatment of Early Allergic and Late Inflammatory Symptoms of Allergic Rhinitis with <i>Petasites Hybridus</i> Leaf Extract (Ze 339): Results of a Noninterventional Observational Study in Switzerland 
260 |b MDPI AG,   |c 2021-02-01T00:00:00Z. 
500 |a 10.3390/ph14030180 
500 |a 1424-8247 
520 |a The primary objective of this noninterventional, observational study was to assess the effectiveness of the <i>Petasites hybridus</i> leaf extract (Ze 339) on early allergic and late inflammatory symptoms of allergic rhinitis in Swiss outpatients. This study was conducted by general practitioners and allergologists. Data from 226 patients were collected during three documented visits. The intermediate visit was ideally made 2-4 weeks after the baseline visit, followed by the final visit approximately 2-4 months later. The mean study duration was 63 days, with 75% of patients being treated for at least 4 weeks. Of the patients, 58.5% started with Ze 339 monotherapy, and 41.5% received other antiallergic and/or sympathomimetic drugs. In both groups, the allergic total symptom score and the inflammatory total symptom scores were significantly (<i>p</i> < 0.001) reduced, and the scores for quality of life were improved. Both physicians and patients were very satisfied with the treatment and the concept of therapy, not only for short-term (seasonal) therapy but also for long-term therapy. The tolerability was good: only three mild gastrointestinal adverse events occurred. In summary, the effectiveness of <i>P. hybridus</i> leaf extract Ze 339 for the treatment of early allergic and late inflammatory symptoms of allergic rhinitis could be confirmed. 
546 |a EN 
690 |a <i>Petasites</i> <i>hybridus</i> 
690 |a butterbur 
690 |a Ze 339 
690 |a noninterventional study 
690 |a observational study 
690 |a allergic rhinitis 
690 |a Medicine 
690 |a R 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceuticals, Vol 14, Iss 3, p 180 (2021) 
787 0 |n https://www.mdpi.com/1424-8247/14/3/180 
787 0 |n https://doaj.org/toc/1424-8247 
856 4 1 |u https://doaj.org/article/e7ef3da18d5f41c0a534831c59519afc  |z Connect to this object online.